Related Experiment Videos
In vitro activity of BMY-28100, a new oral cephalosporin
1Montefiore Hospital, Department of Medicine, University of Pittsburgh, School of Medicine, Pa.
Chemotherapy
|January 1, 1988
Abstract:
BMY-28100 is a new orally absorbed cephalosporin whose in vitro activity was compared with that of cefaclor. BMY-28100 was more active against Staphylococcus aureus and Haemophilus influenzae than was cefaclor. In addition, there was only a small rise in MIC50 and MIC90 values for BMY-28100 when the inoculum size was increased 100- or 10,000-fold. In contrast, MIC50 and MIC90 values increased significantly for cefaclor with similar increases in inoculum size. These data suggest that BMY-28100 may be a promising agent to test for oral administration in infections caused by S. aureus and H. influenzae.